Page 1

Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance July 30 , 2026 Second quarter 2026 revenue growth of 44 % driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $ 1.34 to $ 1.36 billion , representing growth of 36 % to 38 % PALO ALTO , Calif .-- ( BUSINESS WIRE ) -- Guardant Health , Inc. ( Nasdaq : GH ) , a leading precision oncology company , today reported financial results for the quarter ended June 30 , 2026 . Second Quarter 2026 Financial Highlights For the three - month period ended June 30 , 2026 , as compared to the same period of 2025 : Reported total revenue of $ 335.0 million , an increase of 44 % , driven by : ⋅ Oncology revenue of $ 219.1 million , an increase of 38 % , and approximately 104,000 oncology tests , an increase of 63 % • Biopharma & Data revenue of $ 60.9 million , an increase of 9 % • • Screening revenue of $ 52.9 million , and approximately 66,000 Shield ™ screening tests , compared to $ 14.8 million revenue and 16,000 tests in the prior year period Generated non - GAAP gross margin of 67 % , compared to 66 % for the second quarter of 2025 Recent Operating Highlights • • • Received U.S. Food and Drug Administration ( FDA ) approval for Guardant360® Liquid CDx , the most advanced FDA- approved liquid biopsy panel Presented 38 abstracts at the 2026 American Society of Clinical Oncology Annual Meeting , highlighting the expanding clinical utility of Guardant's portfolio Received FDA approval for Guardant360® CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS for HER2 ( ERBB2 ) -mutant advanced non - small cell lung cancer • Achieved inclusion of Shield in the American Cancer Society's updated colorectal cancer screening guidelines • Obtained Shield coverage from UnitedHealth Group , the first major commercial insurer to provide coverage Received FDA approval for higher - throughput , lower - COGS Shield workflow " Our second - quarter performance reflected broad - based momentum across the Guardant portfolio , with revenue increasing 44 % year over year , " said Helmy Eltoukhy , co - founder and co - CEO . " Growth was fueled by strong oncology volume , with acceleration across every product . The landmark FDA approval of Guardant360 Liquid CDx further strengthens our portfolio and positions us to drive sustained growth in the years ahead . " " Our team delivered another quarter of exceptional growth for Shield , and we are excited about several important milestones that reinforce its expanding role in colorectal cancer screening , " said AmirAli Talasaz , co - founder and co - CEO . " The